Observational analysis shows enhanced tumour-specific activation with light-activated toll-like receptors, suggesting improved cancer immunotherapy outcomes.
Although innate immune modulators have shown promise as cancer immunotherapeutics, their clinical application is hindered by the challenge of achieving tumour-specific activation while minimizing systemic immune-related toxicity. Nanoscale metal–organic frameworks...
No takes yet. Share an insight, caveat, or question.
Mao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: